CNS Drugs

, Volume 16, Issue 6, pp 405–418 | Cite as

Differentiation of Multiple Sclerosis Subtypes

Implications for Treatment
Review Article

Abstract

There has been tremendous progress in the immunomodulatory treatment of multiple sclerosis (MS) during recent years. With the introduction of interferon-β, glatiramer acetate and mitoxantrone (recently registered for MS in the US), there are at least three therapeutic strategies that have proven effective in large phase III studies. However, not all patients with MS respond well to treatment with these drugs. This may largely be a consequence of disease heterogeneity.

From a clinical perspective, patients with different disease courses show different treatment responses. Patients with relapsing-remitting MS are more likely to respond to immunomodulatory therapy than those with a progressive disease course. Studies of patients with secondary progressive MS have yielded inconsistent results and, so far, there has been no positive phase III study of immunomodulatory therapy in patients with primary progressive MS.

Pathological evidence indicates that subtyping based on clinical findings alone does not reflect actual disease heterogeneity. In a large series of biopsy and autopsy specimens, at least four subtypes could be identified with respect to oligodendrocyte/myelin pathology and immunopathology. As long as the only method of identifying subtypes of disease is histopathology, differential therapy will remain a future goal. Thus, there is an urgent need for in vivo markers of immunopathogenesis in an individual patient that would allow treatment to be specifically directed towards a given pathological focus.

However, at least from a theoretical point of view, some therapeutic approaches appear very attractive. Plasmapheresis and/or intravenous immunoglobulins could most plausibly be the best approach for the immunopathological subtype of MS, which is characterised by antibody and complement deposition next to demyelinated axons, in order to remove antibodies. The subtype of MS that is associated with heavy macrophage activation, T cell infiltration and expression of inflammatory mediator molecules, including tumour necrosis factor-α, may be most likely to respond to immunomodulation with interferon-β or glatiramer acetate. There are other subtypes of MS in which viral infection or oligodendrocyte degeneration, rather than autoimmunity, appear to play a role. It is possible that these could benefit from antiviral therapy, oligodendrocyte protection or oligodendrocyte transplantation, although therapies based on these latter approaches have yet to be developed.

References

  1. 1.
    Lassmann H. Pathology of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, et al., editors. McAlpine’s multiple sclerosis. 3rd ed. London: Churchill Livingstone, 1998: 323–358Google Scholar
  2. 2.
    Weinshenker BG, Rice GP, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114 (Pt 2): 1045–56PubMedCrossRefGoogle Scholar
  3. 3.
    Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116: 117–34PubMedCrossRefGoogle Scholar
  4. 4.
    Paolino E, Fainardi E, Ruppi P, et al. A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60: 572–5PubMedCrossRefGoogle Scholar
  5. 5.
    Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1422–7CrossRefGoogle Scholar
  6. 6.
    Lucchinetti CF, Brück W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996; 6: 259–74PubMedCrossRefGoogle Scholar
  7. 7.
    Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707–17PubMedCrossRefGoogle Scholar
  8. 8.
    Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907–11PubMedCrossRefGoogle Scholar
  9. 9.
    Weinshenker BG. The natural history of multiple sclerosis: update 1998. Semin Neurol 1998; 18: 301–7PubMedCrossRefGoogle Scholar
  10. 10.
    Rieckmann P, Toyka KV. Escalating immunotherapy of multiple sclerosis. Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group (MSTCG). Eur Neurol 1999; 42: 121–7PubMedGoogle Scholar
  11. 11.
    Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112 (Pt 1): 133–46PubMedCrossRefGoogle Scholar
  12. 12.
    Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996; 119: 715–22PubMedCrossRefGoogle Scholar
  13. 13.
    Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 1998; 121: 687–97PubMedCrossRefGoogle Scholar
  14. 14.
    Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999; 122 (Pt 10): 1941–50PubMedCrossRefGoogle Scholar
  15. 15.
    Weinshenker BG. Progressive forms of MS: classification streamlined or consensus overturned? Lancet 2000; 355: 162–3PubMedCrossRefGoogle Scholar
  16. 16.
    Gayou A, Brochet B, Dousset V. Transitional progressive multiple sclerosis: a clinical and imaging study. J Neurol Neurosurg Psychiatry 1997; 63: 396–8PubMedCrossRefGoogle Scholar
  17. 17.
    Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain 1997; 120: 1085–96PubMedCrossRefGoogle Scholar
  18. 18.
    Amato MP, Ponziani G, Bartolozzi ML, et al. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999; 168: 96–106PubMedCrossRefGoogle Scholar
  19. 19.
    Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999; 67: 148–52PubMedCrossRefGoogle Scholar
  20. 20.
    Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898–904PubMedCrossRefGoogle Scholar
  21. 21.
    Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576–82PubMedCrossRefGoogle Scholar
  22. 22.
    Sorensen PS. Biological markers in body fluids for activity and progression in multiple sclerosis. Mult Scler 1999 Aug; 5(4): 287–90PubMedCrossRefGoogle Scholar
  23. 23.
    Stevenson VL, Miller DH, Rovaris M, et al. Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 1999; 52: 839–45PubMedCrossRefGoogle Scholar
  24. 24.
    Duran I, Martinez-Caceres EM, Rio J, et al. Immunological profile of patients with primary progressive multiple sclerosis: expression of adhesion molecules. Brain 1999; 122: 2297–307PubMedCrossRefGoogle Scholar
  25. 25.
    Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285–91PubMedCrossRefGoogle Scholar
  26. 26.
    Lucchinetti C, Brück W, Parisi J, et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain 1999; 122: 2279–95PubMedCrossRefGoogle Scholar
  27. 27.
    Sheean GL, Murray NM, Rothwell JC, et al. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 1998; 121 (Pt 5): 967–75PubMedCrossRefGoogle Scholar
  28. 28.
    Miller DM, Weinstock-Guttman B, Bethoux F, et al. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 2000; 6: 267–73PubMedGoogle Scholar
  29. 29.
    Beck RW. The optic neuritis treatment trial: three-year follow-up results. Arch Ophthalmol 1995; 113(2): 136–7PubMedCrossRefGoogle Scholar
  30. 30.
    Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998; 51: 239–45PubMedCrossRefGoogle Scholar
  31. 31.
    Cazzato G, Mesiano T, Antonello R, et al. Double-blind, placebocontrolled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol 1995; 35: 193–8PubMedCrossRefGoogle Scholar
  32. 32.
    Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682–9PubMedCrossRefGoogle Scholar
  33. 33.
    Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled study. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655-61Google Scholar
  34. 34.
    Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Neurology 1995; 45: 1277-85Google Scholar
  35. 35.
    Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. The UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 662–7Google Scholar
  36. 36.
    Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–94PubMedCrossRefGoogle Scholar
  37. 37.
    Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998 Nov 7; 352 (9139): 1498-504Google Scholar
  38. 38.
    Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta-1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999; 46: 197–206PubMedCrossRefGoogle Scholar
  39. 39.
    PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001 Jun 26; 56(12): 1628–36CrossRefGoogle Scholar
  40. 40.
    Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive. European Study Group on Interferon β-1b in Secondary Progressive MS. Lancet 1998; 352: 1491-7Google Scholar
  41. 41.
    Goodkin D. The North American secondary progressive multiple sclerosis trial: clinical results. Satellite (Betaferon® in Secondary Progressive Multiple Sclerosis) at the 10th European Neurological Society meeting; 2000 Jun 18–22; JerusalemGoogle Scholar
  42. 42.
    Cohen JA, Goodman AD, Heidenreich FR, et al. Results of IMPACT, a phase 3 trial of interferon beta-1a in secondary progressive multiple sclerosis. 53rd American Academy of Neurology meeting; 2001 May 5–11; Philadelphia (PA)Google Scholar
  43. 43.
    Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Secondary Progression Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Neurology 2001; 56: 1496-504Google Scholar
  44. 44.
    O’Neill JK, Baker D, Morris MM, et al. Optic neuritis in chronic relapsing experimental allergic encephalomyelitis in Biozzi ABH mice: demyelination and fast axonal transport changes in disease. J Neuroimmunol 1998; 82: 210–8PubMedCrossRefGoogle Scholar
  45. 45.
    Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001; 58: 961–7PubMedCrossRefGoogle Scholar
  46. 46.
    Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995; 45: 1268–76PubMedCrossRefGoogle Scholar
  47. 47.
    Comi G, Filippi M, Wolinsky JS. European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging — measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290–7Google Scholar
  48. 48.
    Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349: 589–93PubMedCrossRefGoogle Scholar
  49. 49.
    Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273–81PubMedCrossRefGoogle Scholar
  50. 50.
    Lisak RP. Intravenous immunoglobulins in multiple sclerosis. Neurology 1998; 51(6 Suppl. 5): S25–9PubMedCrossRefGoogle Scholar
  51. 51.
    Miller A, Shapiro S, Gershtein R, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113–21PubMedCrossRefGoogle Scholar
  52. 52.
    Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50: 398–402PubMedCrossRefGoogle Scholar
  53. 53.
    Orvieto R, Achiron R, Rotstein Z, et al. Pregnancy and multiple sclerosis: a 2-year experience. Eur J Obstet Gynecol Reprod Biol 1999;82: 191–4PubMedCrossRefGoogle Scholar
  54. 54.
    Achiron A, Rotstein Z, Noy S, et al. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 1996; 243: 25–8PubMedCrossRefGoogle Scholar
  55. 55.
    Kazatchkine MD, Bellon B, Kaveri SV. Mechanisms of action of intravenous immunoglobulin (IVIG). Mult Scler 2000; 6Suppl. 2: S24–6, discussion S33PubMedGoogle Scholar
  56. 56.
    Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051–5PubMedCrossRefGoogle Scholar
  57. 57.
    Cavazzuti M, Merelli E, Tassone G, et al. Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study. Eur Neurol 1997; 38: 284–90Google Scholar
  58. 58.
    Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebocontrolled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153–9PubMedCrossRefGoogle Scholar
  59. 59.
    Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112–8PubMedCrossRefGoogle Scholar
  60. 60.
    US Department of Health and Human Services. Peripheral & Central Nervous System Drugs Advisory Committee. Mitoxantrone for multiple sclerosis [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/slides/3582s1b/index.htm [Accessed 1 Mar 2002]
  61. 61.
    Cursiefen S, Flachenecker P, Toyka KV, et al. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis. Eur Neurol 2000; 43: 186–7PubMedCrossRefGoogle Scholar
  62. 62.
    Comabella M, Balashov K, Issazadeh S, et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998; 102: 671–8PubMedCrossRefGoogle Scholar
  63. 63.
    Smith DR, Balashov KE, Hafler DA, et al. Immune deviation following pulse cyclophosphamide/methylprednisolonetreatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 1997; 42: 313–8PubMedCrossRefGoogle Scholar
  64. 64.
    Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910–8PubMedCrossRefGoogle Scholar
  65. 65.
    Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878–86PubMedCrossRefGoogle Scholar
  66. 66.
    Mandalfino P, Rice G, Smith A, et al. Bone marrow transplantation in multiple sclerosis. J Neurol 2000; 247: 691–5PubMedCrossRefGoogle Scholar
  67. 67.
    Kozak T, Havrdova E, Pit’ha J, et al. Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. Transplant Proc 2001 May; 33(3): 2179–81PubMedCrossRefGoogle Scholar
  68. 68.
    Openshaw H, Lund BT, Kashyap A, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000; 6(5A): 563–75PubMedCrossRefGoogle Scholar
  69. 69.
    Burt RK, Traynor A, Burns W. Hematopoietic stem cell transplantation of multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. Cancer Treat Res 1999; 101: 157–84PubMedCrossRefGoogle Scholar
  70. 70.
    Fassas A, Anagnostopoulos A, Kazis A, et al. Autologous stem cell transplantation in progressive multiple sclerosis — an interim analysis of efficacy. J Clin Immunol 2000 Jan; 20(1): 24–30PubMedCrossRefGoogle Scholar
  71. 71.
    Burt RK, Traynor AE, Cohen B, et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 1998 Mar; 21(6): 537–41PubMedCrossRefGoogle Scholar
  72. 72.
    Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997 Oct; 20(8): 631–8PubMedCrossRefGoogle Scholar
  73. 73.
    Comi G, Kappos L, Clanet M, et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group. J Neurol 2000; 247: 376–82PubMedCrossRefGoogle Scholar
  74. 74.
    Saiz A, Marcos MA, Graus F, et al. No evidence of CNS infection with Chlamydia pneumoniae in patients with multiple sclerosis. J Neurol 2001; 248: 617–8PubMedCrossRefGoogle Scholar
  75. 75.
    Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115–21PubMedCrossRefGoogle Scholar
  76. 76.
    Niehaus A, Shi J, Grzenkowski M, et al. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann Neurol 2000; 48: 362–71PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Department of NeurologyRuppiner Kliniken GmbHNeuruppinGermany
  2. 2.Department of NeuropathologyCharitéBerlinGermany

Personalised recommendations